利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.015 秒)

    Method For Identifying At Risk Cardiovascular Disease Patients
    3.
    发明申请
    Method For Identifying At Risk Cardiovascular Disease Patients 审中-公开
    识别风险心血管疾病患者的方法

    公开(公告)号：US20090188796A1

    公开(公告)日：2009-07-30

    申请号：US12197694

    申请日：2008-08-25

    申请人： David Shewmake ,  Frank Ruderman ,  Christopher Boggess ,  Faith Clendenen

    发明人： David Shewmake ,  Frank Ruderman ,  Christopher Boggess ,  Faith Clendenen

    IPC分类号： G01N27/447

    CPC分类号： G01N33/92 ,  C25B1/285 ,  G01N2800/32 ,  G01N2800/52 ,  Y10T436/104165

    摘要： The invention provides a data base of LDL, I, IIa, IIb, IIIa, IIb, IVa, IVb and HDL2a, HDL2b, HDL 3a, HDL 3b and HDL 3c together with patient data such as HDL-C, LDL-C, Apo A, ApoB, Lp(a) and patient personal data useful for treatment, diagnosing, and monitoring cardiovascular disease. The data base contains the LDL and HDL subfraction data in quantitative mg/dl values and permits deriving relationship amongst the LDL and HDL values and cardiovascular disease. Quantitative data permits more effective treatment and monitoring of cardiovascular disease. For example, quantitative differences in LDL and HDL subclass levels can determine the need for more or less aggressive treatment. The data base which includes patient events, procedures, interventions which is correlated to LDL and HDl quantitative subclass data permits development of personalized patient treatment plans and monitoring the effectiveness of such treatment. Thus, LDL and HDL quantitative subfraction data can be used to more effectively treat and monitor cardiovascular disease.The invention, for example, provides a method for identifying patients with normal NCEP lipid levels who are in need of treatment for cardiovascular disease comprising measuring one or more LDL or HDL particle subclass levels and identifying abnormal LDL or HDL subclass levels. LDL III a & b and HDL 2b are preferred subclasses.

    摘要翻译： 本发明提供LDL，I，IIa，IIb，IIIa，IIb，IVa，IVb和HDL2a，HDL2b，HDL 3a，HDL 3b和HDL 3c的数据库以及患者数据如HDL-C，LDL-C，Apo A，ApoB，Lp（a）和患者个人资料可用于治疗，诊断和监测心血管疾病。 数据库包含定量mg / dl值中的LDL和HDL次级分数据，并允许LDL和HDL值与心血管疾病之间的关系。 定量数据可以更有效地治疗和监测心血管疾病。 例如，LDL和HDL亚类水平的定量差异可以确定对或多或少积极治疗的需要。 包括与LDL和HDI定量亚类数据相关的患者事件，程序，干预措施的数据库允许开发个性化的患者治疗计划并监测此类治疗的有效性。 因此，LDL和HDL定量分数据可用于更有效地治疗和监测心血管疾病。 例如，本发明提供了一种用于鉴定需要治疗心血管疾病的正常NCEP脂质水平的患者的方法，包括测量一种或多种LDL或HDL颗粒亚类水平并鉴定异常的LDL或HDL亚类水平。 LDL III a＆b和HDL 2b是优选的亚类。

    Internet based health management system for identifying and minimizing risk factors contributing to metabolic syndrome
    6.
    发明申请
    Internet based health management system for identifying and minimizing risk factors contributing to metabolic syndrome 审中-公开
    基于互联网的健康管理系统，用于识别和最小化造成代谢综合征的危险因素

    公开(公告)号：US20070068539A1

    公开(公告)日：2007-03-29

    申请号：US11522650

    申请日：2006-09-18

    申请人： Christopher Hall ,  Vance Lanier ,  David Shewmake ,  Frank Ruderman ,  Matthew Banet ,  Randon Schultz ,  Marshal Dhillon ,  Adam Fleming ,  Henk Visser

    发明人： Christopher Hall ,  Vance Lanier ,  David Shewmake ,  Frank Ruderman ,  Matthew Banet ,  Randon Schultz ,  Marshal Dhillon ,  Adam Fleming ,  Henk Visser

    IPC分类号： G06F19/00

    CPC分类号： A61B5/0022 ,  A61B5/021 ,  A61B5/024 ,  A61B5/145 ,  A61B5/14532 ,  G06F19/3481 ,  G06Q50/22 ,  G16H10/20 ,  G16H10/60 ,  G16H15/00

    摘要： The invention provides a system that determines if a patient has Metabolic Syndrome, and in response provides a disease-management program that helps reduce medical risks associated with this malady. The system features a device configured to collect glucose information and blood pressure information, and then transmit this information to a central computer system. The system also includes a database configured to receive triglyceride information and cholesterol information from an external blood test, and a central computer system featuring: 1) a communication interface configured to communicate with the device to receive glucose and blood pressure information and with the database to receive triglyceride and cholesterol information; 2) a user interface configured to accept patient information; and 3) a processor configured to operate an algorithm that processes the glucose, blood pressure, triglyceride, cholesterol, and patient information to determine if the patient has Metabolic Syndrome.

    摘要翻译： 本发明提供了一种确定患者是否具有代谢综合征的系统，并且作为响应提供了有助于减少与该疾病相关的医疗风险的疾病管理程序。 该系统具有被配置为收集葡萄糖信息和血压信息的设备，然后将该信息发送到中央计算机系统。 该系统还包括配置为从外部血液测试中接收甘油三酯信息和胆固醇信息的数据库，以及中央计算机系统，其特征在于：1）通信接口，被配置为与设备通信以接收葡萄糖和血压信息，并且与数据库 接受甘油三酯和胆固醇信息; 2）被配置为接收患者信息的用户界面; 以及3）处理器，其被配置为操作处理葡萄糖，血压，甘油三酯，胆固醇和患者信息以确定患者是否具有代谢综合征的算法。

    Method for selecting an optimal diet and exercise regimen based on a LDL and HDL subclass determination
    7.
    发明申请
    Method for selecting an optimal diet and exercise regimen based on a LDL and HDL subclass determination 有权
    基于LDL和HDL亚类测定选择最佳饮食和运动方案的方法

    公开(公告)号：US20050009193A1

    公开(公告)日：2005-01-13

    申请号：US10854402

    申请日：2004-05-26

    申请人： Amy Roberts ,  David Shewmake

    发明人： Amy Roberts ,  David Shewmake

    IPC分类号： G01N33/92 ,  G06Q10/00 ,  G06F17/60

    CPC分类号： G06Q10/10 ,  G01N33/92 ,  G01N2800/044 ,  G06F19/00 ,  G06Q50/24

    摘要： The invention provides novel methods for selecting an optimal diet and exercise regimen for a patient based on the consideration of several factors, including low density lipoprotein (LDL) and high density lipoprotein (HDL) subclass levels. Furthermore, the invention provides novel methods for treating a patient, comprising selecting an optimal diet and exercise regimen and monitoring the patient. Patients appropriate for the methods of the invention include, for example, those with cardiovascular disease (CVD) or at risk of developing CVD. In contrast to prior methods, the methods of the invention are based on the measurement of risk factors, including LDL and HDL subclass levels, that have not previously been used to select a diet and exercise regimen.

    摘要翻译： 本发明提供了基于对低密度脂蛋白（LDL）和高密度脂蛋白（HDL）亚类水平的几个因素的考虑，为患者选择最佳饮食和运动方案的新方法。 此外，本发明提供了治疗患者的新方法，包括选择最佳饮食和运动方案并监测患者。 适用于本发明方法的患者包括例如具有心血管疾病（CVD）或有发展CVD风险的患者。 与现有方法相反，本发明的方法是基于以前未用于选择饮食和运动方案的危险因素（包括LDL和HDL亚类水平）的测量。